Breaking: Transcarent to acquire Accolade for $621M creating benefits tech giant

Transcarent CEO Glen Tullman spent much of 2024 hinting that his health benefits upstart might be shopping around for acquisitions.

Log In    Subscribe BREAKING NEWS   Transcarent to acquire Accolade for $621 million creating benefits tech giant By Mario Aguilar Greg Allen/Invision/AP Transcarent CEO Glen Tullman spent much of 2024 hinting that his health benefits upstart might be shopping around for acquisitions, and just over a week into the new year he's making good on it: Transcarent on Wednesday announced it was buying Accolade, another benefits company, for $621 million — more than double Accolade's share price on Tuesday. READ MORE Sign up for STAT Health Tech Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve. Get the newsletter in your inbox. In Case You Missed It 1   How UnitedHealth harnesses its physician empire to squeeze profits out of patients By Bob Herman, Tara Bannow, Casey Ross, and Lizzy Lawrence 2   With a major patent cliff coming, will JPM play host to some serious deal-making? By Allison DeAngelis and Adam Feuerstein 3   Wearable maker ActiGraph acquires assets from Biofourmis to boost clinical trial offerings By Mario Aguilar 4   Hospitals now know how some health AI tools were developed. Will that change anything? By Mario Aguilar Don't miss out on another STAT Investigation Unlock the world of health and medicine with a subscription to STAT+ Learn more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us